152 related articles for article (PubMed ID: 12471654)
1. [ASSENT III and GUSTO V: is it the end of combination therapy with GPIIb/IIIa blockers and thrombolytics in myocardial infarction?].
Vahanian A
Ann Cardiol Angeiol (Paris); 2002 Jan; 51(1):6-7. PubMed ID: 12471654
[No Abstract] [Full Text] [Related]
2. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
Topol EJ;
Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410
[TBL] [Abstract][Full Text] [Related]
3. [GPIIb/IIIa blockers for optimizing thrombolysis in acute myocardial infarct].
Nordt TK; Peter K; Bode C
Herz; 2001 Apr; 26 Suppl 1():42-5. PubMed ID: 11349626
[TBL] [Abstract][Full Text] [Related]
4. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
[TBL] [Abstract][Full Text] [Related]
5. Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials.
Califf RM
Am Heart J; 1999 Jul; 138(1 Pt 2):S12-5. PubMed ID: 10385786
[TBL] [Abstract][Full Text] [Related]
6. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
Gurm HS; Lincoff AM; Lee D; Tang WH; Jia G; Booth JE; Califf RM; Ohman EM; Van de Werf F; Armstrong PW; Guetta V; Wilcox R; Topol EJ;
J Am Coll Cardiol; 2004 Feb; 43(4):542-8. PubMed ID: 14975461
[TBL] [Abstract][Full Text] [Related]
7. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
Dunn A
Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
[No Abstract] [Full Text] [Related]
8. Management of acute coronary syndromes.
Schulman SP; Fessler HE
Am J Respir Crit Care Med; 2001 Sep; 164(6):917-22. PubMed ID: 11587971
[No Abstract] [Full Text] [Related]
9. Too much, too little, or none at all: dealing with substandard and fake drugs.
Wan Po AL
Lancet; 2001 Jun; 357(9272):1904. PubMed ID: 11425409
[No Abstract] [Full Text] [Related]
10. Confusion in reperfusion.
Gibson CM
J Am Coll Cardiol; 2003 Oct; 42(7):1186-7. PubMed ID: 14522477
[No Abstract] [Full Text] [Related]
11. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
[TBL] [Abstract][Full Text] [Related]
12. Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.
Merlini PA; Repetto A; Andreoli AM; Ricci S; Lombardi A; Finardi A; Dipasquale G; Lamponi M; Mannucci PM; Ardissino D
Am J Cardiol; 2004 Jan; 93(2):195-8. PubMed ID: 14715345
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Hobbach HP; Schuster P
Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
[TBL] [Abstract][Full Text] [Related]
14. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Roe MT; Sapp SK; Lincoff AM
Cleve Clin J Med; 2000 Feb; 67(2):131-40. PubMed ID: 10680279
[TBL] [Abstract][Full Text] [Related]
15. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.
Simoons ML;
Lancet; 2001 Jun; 357(9272):1915-24. PubMed ID: 11425411
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146
[TBL] [Abstract][Full Text] [Related]
17. GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.
Chew DP; Moliterno DJ
Cleve Clin J Med; 2001 Dec; 68(12):1017-23. PubMed ID: 11765119
[TBL] [Abstract][Full Text] [Related]
18. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
Dubois CL; Belmans A; Granger CB; Armstrong PW; Wallentin L; Fioretti PM; López-Sendón JL; Verheugt FW; Meyer J; Van de Werf F;
J Am Coll Cardiol; 2003 Oct; 42(7):1178-85. PubMed ID: 14522476
[TBL] [Abstract][Full Text] [Related]
19. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
Ellis SG; Armstrong P; Betriu A; Brodie B; Herrmann H; Montalescot G; Neumann FJ; Smith JJ; Topol E;
Am Heart J; 2004 Apr; 147(4):E16. PubMed ID: 15077099
[TBL] [Abstract][Full Text] [Related]
20. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
